Cancer Drug Encyclopedia

Adjuvant therapy after tumor resection in patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations; first-line treatment for metastatic EGFR-mutated NSCLC; and EGFR T790M mutation-positive metastatic NSCLC.

Locally advanced or metastatic urothelial carcinoma, non-small cell lung cancer, extensive-stage small cell lung cancer (ES-SCLC), and unresectable hepatocellular carcinoma in combination with bevacizumab.

Treatment of patients with castration-resistant prostate cancer (CRPC) and metastatic castration-sensitive prostate cancer (mCSPC).